The Lethal Clone in Prostate Cancer: Redefining the Index

Slides:

Advertisements

Similar presentations

Early Detection of Prostate Cancer in 2007

Advertisements

The PSA Era is not Over for Prostate Cancer

Volume 59, Issue 2, Pages (February 2011)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

Testosterone Therapy in Men With Prostate Cancer

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 61, Issue 6, Pages (June 2012)

Volume 70, Issue 6, Pages (December 2016)

Volume 71, Issue 2, Pages (February 2017)

Volume 64, Issue 4, Pages (October 2013)

Volume 69, Issue 1, Pages (January 2016)

Let the Games Begin (with EAU Approval)

Prostate Cancer Epidemic in Sight?

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

Kathie Alexina Wong, Mark Wass, Kay Thomas European Urology

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 68, Issue 5, Pages (November 2015)

Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey John B. McKinlay, Carol L. Link European.

Elizabeth K. Bancroft, Rosalind A. Eeles

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 70, Issue 3, Pages (September 2016)

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 68, Issue 1, Pages (July 2015)

Shaheen Alanee, Kasmintan Schrader, Kenneth Offit European Urology

Volume 72, Issue 3, Pages (September 2017)

Counselling the Prostate Cancer Patient

The Mutational Landscape of Prostate Cancer

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Cliques and Schisms of Cancer Genes

Global Burden of Urologic Cancers, 1990–2013

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 6, Pages (June 2008)

Volume 66, Issue 6, Pages (December 2014)

Mark A. Rubin, Gabriele Girelli, Francesca Demichelis European Urology

Leonard S. Marks, Jiaoti Huang European Urology

Volume 63, Issue 3, Pages (March 2013)

Volume 62, Issue 4, Pages (October 2012)

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Use of the National Health and Nutrition Examination Survey to Calculate the Impact of Obesity and Diabetes on Cost and Prevalence of Urolithiasis in.

Karl-Dietrich Sievert, Bastian Amend, Arnulf Stenzl European Urology

Volume 62, Issue 3, Pages (September 2012)

Volume 62, Issue 6, Pages (December 2012)

Volume 62, Issue 3, Pages (September 2012)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

DNA Repair in Prostate Cancer: Biology and Clinical Implications

Testicular Cancer Variations in Time and Space in Europe

Volume 53, Issue 1, Pages (January 2008)

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

European Urology is “Your” Journal

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Economic Burden of Bladder Cancer Across the European Union

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Volume 54, Issue 3, Pages (September 2008)

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

The Lethal Clone in Prostate Cancer: Redefining the Index Christopher E. Barbieri, Francesca Demichelis, Mark A. Rubin European Urology Volume 66, Issue 3, Pages 395-397 (September 2014) DOI: 10.1016/j.eururo.2013.12.052 Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 1 Speckle-type POZ protein (SPOP), phosphatase and tensin homolog (PTEN), and tumor protein 53 (TP53) abnormalities across the spectrum of early and advanced prostate cancer. SPOP mutations occur in 10–15% of prostate cancer, with relatively stable prevalence across stages of disease. Mutations and deletions in PTEN and TP53 increase in frequency with advanced disease (but do not always occur together). Co-occurrence of SPOP mutations and PTEN and TP53 lesions are uncommon in early prostate cancer, but begin to overlap with advanced disease. European Urology 2014 66, 395-397DOI: (10.1016/j.eururo.2013.12.052) Copyright © 2013 European Association of Urology Terms and Conditions